NASDAQ:CTXR - Citius Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 293.70 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.27
▲ +0.1 (8.55%)

This chart shows the closing price for CTXR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Citius Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTXR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTXR

Analyst Price Target is $5.00
▲ +293.70% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 293.70% upside from the last price of $1.27.

This chart shows the closing price for CTXR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Citius Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/11/2022Maxim GroupInitiated CoverageBuy$4.00Medium
1/18/2022HC WainwrightBoost Price TargetBuy$4.00 ➝ $6.00Medium
11/30/2021Maxim GroupInitiated CoverageBuy$4.00Medium
3/1/2021HC WainwrightReiterated RatingBuyLow
2/25/2021Dawson JamesReiterated RatingBuy$6.00Low
9/17/2020Dawson JamesReiterated RatingBuyLow
8/18/2020HC WainwrightReiterated RatingBuy$4.00Low
5/19/2020HC WainwrightReiterated RatingBuy$4.00High
1/24/2020HC WainwrightReiterated RatingBuy$4.00High
9/6/2019Dawson JamesInitiated CoverageBuy$7.00N/A
2/7/2019HC WainwrightReiterated RatingBuy$3.00High
5/23/2018HC WainwrightInitiated CoverageBuy$11.00High
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/18/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/18/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Citius Pharmaceuticals logo
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Read More

Today's Range

Now: $1.27
Low: $1.16
High: $1.30

50 Day Range

MA: $0.95
Low: $0.88
High: $1.27

52 Week Range

Now: $1.27
Low: $0.83
High: $2.35

Volume

915,912 shs

Average Volume

794,524 shs

Market Capitalization

$185.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Citius Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Citius Pharmaceuticals in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for CTXR.

What is the current price target for Citius Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Citius Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 293.7%. HC Wainwright has the highest price target set, predicting CTXR will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for Citius Pharmaceuticals in the next year.
View the latest price targets for CTXR.

What is the current consensus analyst rating for Citius Pharmaceuticals?

Citius Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTXR will outperform the market and that investors should add to their positions of Citius Pharmaceuticals.
View the latest ratings for CTXR.

What other companies compete with Citius Pharmaceuticals?

How do I contact Citius Pharmaceuticals' investor relations team?

Citius Pharmaceuticals' physical mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company's listed phone number is (908) 967-6677 and its investor relations email address is [email protected] The official website for Citius Pharmaceuticals is www.citiuspharma.com. Learn More about contacing Citius Pharmaceuticals investor relations.